AJP CME Course for June 2008: Reduced Amygdala Response to Fearful Expressions in Children and Adolescents With Callous-Unemotional Traits and Disruptive Behavior Disorders

The participant will understand the neural processes involved in emotional regulation in children.

Information to Participants

OBJECTIVES. After evaluating a specific journal article, participants should be able to demonstrate an increase in their knowledge of clinical medicine. Participants should be able to understand the contents of a selected research or review article and to apply the new findings to their clinical practice.

PARTICIPANTS. This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.

EXPLANATION OF HOW PHYSICIANS CAN PARTICIPATE AND EARN CREDIT. In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the CME quiz online at cme.psychiatryonline.org and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit^TM).

CREDITS. The APA designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Psychiatric Assocation (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Estimated Time to Complete Course: 1 hour.
Begin Date for Course: June 1, 2008.
End Date for Course: June 31, 2010.

Information on Courses

Title: Reduced Amygdala Response to Fearful Expressions in Children and Adolescents With Callous-Unemotional Traits and Disruptive Behavior Disorders
Faculty: Abigail A. Marsh, Ph.D., Elizabeth C. Finger, M.D., Derek G.V. Mitchell, Ph.D., Marguerite E. Reid, Courtney Sims, David S. Kosson, Ph.D., Kenneth E. Towbin, M.D., Ellen Leibenluft, M.D., Daniel S. Pine, M.D., R.J.R. Blair, Ph.D.
Affiliations: National Institute of Mental Health (A.A.M., E.C.F., M.E.R., C.S., D.S.K., K.E.T., E.L., D.S.P., R.J.R.B.); Department of Psychiatry and Department of Anatomy and Cell Biology, University of Western Ontario (D.G.V.M.); and Department of Psychology, Rosalind Franklin University of Medicine and Science (D.S.K.).
Disclosures: All authors report no competing interests.
Discussion of unapproved or investigational use of products*: None

* American Psychiatric Association policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.

• Take this course